Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015081 | 0.88 | FKBP1A (0.33) | GAAFKBP1APEPDMMP2ANPEP | |
| SCHEMBL3022604 | 0.87 | ALDH1A1 (0.34) | GAAFKBP1AMAPTALDH1A1 | |
| SCHEMBL3016583 | 0.84 | MMP2 (0.38) | PEPDMMP2ANPEPBRD4TP53 | |
| SCHEMBL3016989 | 0.75 | ALDH1A1 (0.34) | GAAFKBP1ATP53MAPTALDH1A1 | |
| SCHEMBL3019979 | 0.73 | ALDH1A1 (0.37) | FKBP1AMAPTALDH1A1 | |
| SCHEMBL3013238 | 0.68 | TSHR (0.39) | PEPDMMP2ANPEPBRD4TP53 | |
| SCHEMBL3018094 | 0.67 | TSHR (0.38) | GAAMMP2ANPEPBRD4TP53 | |
| SCHEMBL25872909 | 0.65 | FKBP1A (0.36) | GAAFKBP1APEPDMMP2ANPEP | |
| SCHEMBL3017696 | 0.64 | MMP2 (0.41) | GAAMMP2ANPEPBRD4TP53 | |
| SCHEMBL3019161 | 0.62 | CHRM2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2197882-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | Basf Se (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030649-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | TES, TRRAP, NAAA | GAA 3017/4885FKBP1A 710/4885PEPD 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.